Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.66 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | BAD | Q92934 | 2/20 | 0.45 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12149617 | 0.90 | FDPS (0.67) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149687 | 0.89 | FDPS (0.61) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149663 | 0.88 | FDPS (0.65) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL27861648 | 0.87 | FDPS (0.62) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149637 | 0.87 | FDPS (0.63) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL1378315 | 0.86 | FDPS (0.78) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149693 | 0.85 | FDPS (0.70) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149699 | 0.84 | FDPS (0.74) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149578 | 0.83 | FDPS (0.64) | FDPSMCL1PARP10PARP15MEN1 | |
| SCHEMBL12149598 | 0.83 | FDPS (0.60) | FDPSMCL1PARP10PARP15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | claimed |
| CN-102186803-A | Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors | NOVARTIS AG | 2011-09-14 | — | — | CN | claimed |
| EP-2342173-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010043584-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2010-04-22 | — | — | WO | claimed |
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | disclosed |
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | disclosed |
| EP-2342173-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010043584-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043584-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | FDPS, GGPS1, COASY | FDPS 1/4885MCL1 3077/4885PARP10 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.